The promise of cell-based immunotherapy is giving hope to patients around the globe living with devastating disease; but the future of the cell therapy industry is still unclear. This panel discussion co-hosted by Precision for Medicine and Precision ADVANCE will feature key insights and discussion from advanced therapy leaders on the pros and cons of developing Autologous and Allogeneic cell therapies.
The panel discussion will be moderated by Anshul Mangal (President of Project Farma & Precision ADVANCE) and feature unique insights from Gwendolyn Binder (EVP of Science & Technology at Calabetta Bio), Stephanie Kennedy (Senior Director at PRECISIONadvisors, Precision Value & Health), Megan Liles (VP of Operational Strategy at Precision for Medicine), Chris McDonald (SVP at Kite Pharma), and Bob Valamehr (Chief R&D Officer at Fate Therapeutics).
Attendees will hear key insights from advanced therapy leaders on:
- The current state of the cell therapy landscape and growing number of Autologous and Allogenic cell therapies in clinical trials worldwide
- Unique insights specific to Autologous and Allogenic cell therapies from clinical development, to manufacturing, and commercialization; all while navigating evolving FDA regulations
- The future opportunities and potential risks of both Autologous and Allogenic cell therapies